Is Sanofi (SAN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 22.0% / 30% | 9.2% / 30% | 12.0% / 30% | 0.71% / 5% | ✓ HALAL |
| DJIM | 22.0% / 33% | 9.2% / 33% | 12.0% / 33% | 0.71% / 5% | ✓ HALAL |
| MSCI | 16.0% / 33% | 6.7% / 33% | 8.7% / 33% | 0.71% / 5% | ✓ HALAL |
| S&P | 22.0% / 33% | 9.2% / 33% | 12.0% / 33% | 0.71% / 5% | ✓ HALAL |
| FTSE | 16.0% / 33% | 6.7% / 33% | 8.7% / 50% | 0.71% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 72.3% | |
| Operating Margin | 14.3% | |
| Net Margin | 16.7% | |
| Return on Equity (ROE) | 6.7% | |
| Return on Assets (ROA) | 4.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $10.8B |
| Free Cash Flow | $7.2B |
| Total Debt | $20.3B |
| Debt-to-Equity | 28.3 |
| Current Ratio | 1.1 |
| Total Assets | $126.8B |
Price & Trading
| Last Close | EUR 81.15 |
| 50-Day MA | EUR 79.02 |
| 200-Day MA | EUR 82.56 |
| Avg Volume | 2.3M |
| Beta | 0.4 |
|
52-Week Range
EUR 74.85
| |
About Sanofi (SAN)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. Sanofi has a strategic collaboration with miRecule, Inc. to facilitate the advancement of therapy DUX4, a genetic driver of debilitating muscular disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Purification Calculator
As a halal stock with 0.71% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Sanofi (SAN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sanofi is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Sanofi's debt ratio?
Sanofi's debt ratio is 22.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.0%.
Does Sanofi require dividend purification?
Yes, Sanofi has an impermissible income ratio of 0.71%, which means 0.71% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Sanofi's key financial metrics?
Sanofi has a market capitalization of $98.6B, trailing P/E ratio of 20.3, and revenue of $46.7B. The company maintains a gross margin of 72.3% and a net margin of 16.7%. Return on equity stands at 6.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.